Agenda

The goal of our “performance” is to provide the audience with an entertaining learning experience.

Topics we will cover:
• Scoping a project and preparing the brief
• Choosing an agency
• Interacting with the agency during the project
• Delivery of the project results
The audience can expect to be able to participate actively in the “conversation” and contribute to the program

The ambiguous and changing local regulations as well as the cultural and compliance dimensions could complicate the situation further. This could have costly consequences on the company resources and financial situation. The discussion will focus on the competitive intelligence mitigating factors companies could consider to turn threats into opportunities for overall growth.

focusing on the importance of selected soft skills, character and personal traits. Participants are invited to exchange their experience and stories as well. The outcome is a list of pointers to consider, for both personal professional development as well as helping to identify talents in your organization.

– measuring patient adherence
– the benefits of more communication about patient adherence

• What are some of the qualitative measurements to assess the impact of CI?
• What are some of the quantitative measurements to assess the impact of CI?
• The group leader will discuss and share some examples for his own experience.

o Overview of Phase 3 to approval timelines
o Summary of FDA programs to expedite development of new therapies and how they can impact approval timelines
o Using competitive intelligence to inform approval timelines

However, with increasing complexities surrounding competitive assumptions and the opportunities/challenges they impact within a global environment, many CI professionals find it increasingly difficult to move beyond the “information” provider to “thought-partner” for their stakeholders. At INOVIS, we are progressively dealing with clients struggling to deal with the unknown, with the fear of uncertainty greatly contributing to a lack of agility and competitive fitness across organizations.

Join us for a co-presentation with a leading industry expert and INOVIS as we explore these topics and discuss:
 Real-world examples from Pharma professionals, where overarching uncertainties have impacted business issues
– How was uncertainty addressed?
– What are the learnings?
 How can CI – be it a mindset or specific framework(s) – generate actionable and tangible outcomes to support the current pharma business environment?
 What are the opportunities for high-impact/high value vendor-client activities to better support this area?

Participants will benefit from the vast experience of the presenters and take home ideas and practical considerations to immediately implement as part of their working practices. Moreover, by strengthening and leveraging their client relationships, drawing on specific expertise and experience, CI professionals should leave with more confidence in dealing with the unknown and turning these challenging situations to their opportunity!

• Discover new sources of human intelligence
• Get you more visibility with senior management
• Help you get a promotion

Pharmaceutical companies need access to a wide range of reliable, relevant data helping them to rapidly assess the best path forward for a particular project, trial design, commercial launch strategy, product differentiation or reimbursement negotiation in order to achieve the optimal outcome. New technologies are impacting this evolving landscape in the shape of companion diagnostics and convenient wearables devices, thereby not only making the collection of data important but also emphasizing that analysis of these collected data through the right technology is critical. Uptake and acceptance of expensive new therapies is enhanced if significant benefit to a particular patient segment can be demonstrated, resulting in the need for data granularity and an ability to filter large datasets with a deep background understanding of the disease and patient.

Prescient will address the challenges companies are facing and the increasing demands for predictive analysis.

• “Design Thinking” and its application across the whole organisation
• Digital transformation and the rise of the Chief Digital Officer

However, as leaders, how much time and effort do we invest in creating the optimal working atmosphere where the happiness becomes the fuel that keeps the motivation running?

• What are some of the qualitative measurements to assess the impact of CI?
• What are some of the quantitative measurements to assess the impact of CI?
• The group leader will discuss and share some examples for his own experience.

– measuring patient adherence
– the benefits of more communication about patient adherence

focusing on the importance of selected soft skills, character and personal traits. Participants are invited to exchange their experience and stories as well. The outcome is a list of pointers to consider, for both personal professional development as well as helping to identify talents in your organization.

The ambiguous and changing local regulations as well as the cultural and compliance dimensions could complicate the situation further. This could have costly consequences on the company resources and financial situation. The discussion will focus on the competitive intelligence mitigating factors companies could consider to turn threats into opportunities for overall growth.

From basic research to preclinical R&D to FIH and registrational trials to filing and approval and eventual lifecycle management, each step of the asset journey has unique challenges, questions, indicators, and levers that can be used to predict eventual impact on a given therapeutic landscape. Proactive Worldwide will give an overview of strategies, tools, and ideal personnel to address each of these unique steps in the asset journey. Applying the proper mix of skilled researchers, analysts, and appropriate tools will allow for maximum ROI when conducting competitive monitoring in the pharmaceutical development space, irrespective of therapeutic area.

— Trend analysis of different partnering formats (in/out-licensing, Mergers/Acquisitions, R&D Collaborations, Co-Dev/Co-Mktg. alliances) by TA, development stage, valuation etc.
— Identify the top 3-5 deals from the partnering landscape and the underlying strategic drivers
— The most successful deal makers and what makes them so
— Future Outlook: Is the frenzy likely to continue?

the implications of CI in markets where there are multiple possible futures and where uncertainty is increasing. The Osprey Health Consulting presentation will highlight the reasons for increasing uncertainty about the future of markets and how this challenges strategic decision making in pharma. How CI professionals can adapt to this new world to ensure the information they provide facilitates improved decision making will be discussed. The critical role of CI in informing, supporting and validating strategic decision making in real-time assessments of markets will be explored and models of how this can be achieved will be proposed.

• Leveraging your internal network
• External partners – how to go about it?

While its precise meaning is open for discussion (and in which field is that not the case), the focus on knowledge and insights, versus managing systems and data, has made it a powerful point of view to address real world challenges in the life science / pharma space. At Roche, for example, several large KM projects have been initiated, that look beyond IT to optimise and structure the information flow across functions and sites. The use of Machine Learning is a tool to improve the quality of the information, and various semantic data integration topics help to identify the insights our R&D colleagues are looking for.

objective/budget setting times, Do-It-Yourself Competitive Strategic Workshops (D-I-Y CSW) may sound like a tempting CI approach to offer to cost conscious stakeholders. This no-slides presentation will share personal lessons learned about setting up and executing D-I-Y CSWs, including, on balance, some reflection on agency-driven CSWs

Inability to convince one’s stakeholders to make a different decision based on the competitive situation can lead to mistakes of judgement and ultimately end in failure for an inline or pipeline asset. In order to better understand how to influence executive decisions, one needs to understand the decision-making journey and systems of thinking. In this presentation, we shall explore the two main systems of thinking, mental heuristics, and strategies for eliciting the right responses when communicating with decision-makers.

molecule is currently found, it becomes crucial to predict the future state of the pharma and biotech projects’ pipeline. Stochastic simulation can be applied to understand the dynamics of the drug development process and to assess how likely certain states are expected to materialize, and such outcomes drive decision making across several business processes at Lonza.